Homocysteine as a risk factor for cardiovascular and related disease: Nutritional implications

Nutrition Research Reviews

Volumn 11, Issue 2, 1998, Pages 311-338

  Weir, Donald G ^a   Scott, John M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000545841     PISSN: 09544224     EISSN: None     Source Type: Journal    
DOI: 10.1079/NRR19980020     Document Type: Article

References (170)

1. Adams, M., Smith, P.D., Martin, D., Thompson, J.R., Lodwick, D. & Samani, N.J. (1996). Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM: Monthly Journal of the Association of Physicians 89, 437-444.
2. Alfthan, G., Aro, A. & Gey, K.F. (1997). Plasma homocysteine and cardiovascular disease mortality. Lancet 349, 397.
3. Alfthan, G., Pakkanen, J., Jaubirmen, M. et al. (1994). Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106, 9-16.
4. 12) and folate deficiency. FASEB Journal 7, 1344-1353.
5. Andersson, A., Brattström, L., Israelsson, B., Isaksson, A., Hamfelt, A. & Hultberg, B. (1992a). Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal status. European Journal of Clinical Investigation 22, 79-87.
6. Andersson, A., Hultberg, B., Brattström, L. & Isaksson, A. (1992b). Decreased serum homocysteine in pregnancy. European Journal of Clinical Chemistry & Clinical Biochemistry 30, 377-379.
7. Andus, T., Mollens, C., Geissler, A., Vogl, D., Gross, V., Schmitz, G., Henna, W. & Scholmenick, J. (1996). Elevated homocysteine concentrations in sera of patients with inflammatory bowel disease. Gastroenterology 110, A855(i).
8. Araki, A. & Sako, Y. (1987). Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. Journal of Chromatography: Biomedical Applications 422, 43-52.
9. Arnadottir, M., Hultberg, B., Nilsson-Ehle, P. & Thysell, H. (1996). The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scandinavian Journal of Clinical Laboratory investigation 56, 41-46.
10. Arnesen, E., Refsum, H., Bonaa, K.H., Ueland, P.M., Forde, O.H. & Nordrehaug, J.E. (1995). Serum total homocysteine and coronary heart disease. International Journal of Epidemiology 24, 704-709.
11. Aronson, D.C., Onkenhout, W., Raben, A.M.T.J., Oudenhoven, L.F.I.J., Brommer, E.J.P. & van Bockel, J.H. (1994). Impaired homocysteine metabolism: a risk factor in young adults with atherosclerotic arterial occlusive disease of the leg. British Journal of Surgery 81, 1114-1118.
12. Bachmann, J., Tepel, M., Raidt, H., Riezler, R., Graefe, U., Langer, K. & Zidek, W. (1995). Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. Journal of the American Society of Nephrology 6, 121-125.
13. Blakley, R.L. (1969). The Biochemistry of Folic Acid and Related Pteridines (Frontiers in Biology, vol. 13). Amsterdam: North Holland.
14. Boers, G.H.J., Smals, A.G., Trijbels, F.J., Leermakers, A.I. & Kloppenborg, P.W. (1983). Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. Journal of Clinical Investigation 72, 1971-1976
15. Boers, G.H.J., Smals, A.G.H., Trijbels, F.J.M., Fowler, B., Bakkeren, J.A.J.M., Schoonderwaldt, H.C., Kleijer, W.J. & Kloppenborg, P.W.C. (1985). Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. New England Journal of Medicine 313, 709-715
16. Bostom, A.G., Brosnan, J.T., Hall, B., Nadeau, M.R. & Selhub, J. (1995). Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116, 59-62
17. Bostom, A.G., Shemin, D., Lapane, K.L., Nadeau, M.R., Sutherland, P., Chan, J., Rozen, R., Yoburn, D., Jacques, P.F., Selhub, J. & Rosenberg, I.H. (1996a). Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123, 193-202.
18. Bostom, A.G., Shemin, D., Lapane, K.L., Sutherland, P., Nadeau, M.R., Wilson, P.W., Yobam, D., Bausserman, L., Tofler, G., Jacques, P.F., Selhub, J. & Rosenberg, I.H. (1996b). Hyperhomocysteinaemia, hyperfibrinogenaemia and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 125, 91-101.
19. Boushey, C.J., Beresford, S.A.A., Omenn, O.S. & Motulsky, A.G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA: Journal of the American Medical Association 274, 1049-1057.
20. Brattström, L., Englund, E. & Brun, A. (1987). Does Down syndrome support homocysteine theory of arteriosclerosis? Lancet I, 391-392.
21. Brattström, L.E., Hardebo, J.E. & Hultberg, B.L. (1984). Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 15, 1012-1016.
22. Brattström, L.E., Hultberg, B L. & Hardebo, J.E. (1985). Folic acid responsive post-menopausal homocysteinemia. Metabolism 34, 1073-1077.
23. Brattström, L.E., Israelsson, B., Jeppsson, J.O. & Hultberg, B.L. (1988). Folic acid - an innocuous means to reduce plasma homocysteine. Scandinavian Journal of Clinical and Laboratory Investigation 48, 215-221.
24. Brattström, L., Israelsson, B., Norrving, B., Bergqvist, D., Thörne, J., Hultberg, B. & Hamfelt, A. (1990). Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyrodoxine and folic acid treatment. Atherosclerosis 81, 51-60.
25. Brattström, L , Israelsson, B., Tengborn, L. & Hultberg, B. (1989). Homocysteine, factor VII and antithrombin III in subjects with different gene dosage of cystathionine-β-synthase. Journal of Inherited Metabolic Disease 12, 475-482.
26. Brattström, L., Lindgren, A., Israelsson, B., Andersson, A. & Hultberg, B. (1994). Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. Journal of Internal Medicine 236, 633-641.
27. Brattström, L., Lindgren, A., Israelsson, B., Malinow, M.R., Norrving, B., Upson, B. & Hamfelt, A. (1992). Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. European Journal of Clinical Investigation 22, 214-221.
28. Carson, N.A.J. & Neill, D.W. (1962). Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Archives of Disease in Childhood 37, 505-513.
29. Chadefaux, B., Ceballos, I., Hamet, M., Coude, M., Poissonnier, M., Kamoun, P. & Allard, D. (1988). Is absence of atheroma in Down syndrome due to decreased homocysteine levels? Lancet 2, 741.
30. Chambers, J.C., McGregor, A., Jean-Marie, J. & Koower, J.S. (1998). Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 351, 36-37.
31. 6 and risk of myocardial infarction in US physicians. Journal of the American College of Nutrition 15, 136-143.
32. Chrìstensen, B., Frosst, P., Lussier-Cacan, S., Selhub, J., Goyette, P., Rosenblatt, D., Genest, J. & Rozen, R. (1997). Correlation of a common mutation in the methylene tetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arteriosclerosis, Thrombosis and Vascular Biology 17, 569-571.
33. Corrales, F., Gimenez, A., Alvarez, L., Caballeria, J., Pajares, M.A., Andreu, H., Pares, A., Mato, J.M. & Rodes, J. (1992). S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. Hepatology 16, 1022-1027.
34. Corrales, F., Ochoa, P., Rivas, C., Martin-Lomas, M., Mato, J.M. & Pajares, M.A. (1991). Inhibition of glutathione synthesis in the liver leads to S-adenosyl-L-methionine synthetase reduction. Hepatology 14, 528-533.
35. Cronin, C.C., McPartlin, J.M., Barry, D.G., Ferris, B., Scott, J.M. & Weir, D.G. (1996). Plasma total homocyst(e)ine concentration and micro-vascular complications in insulin-dependent (Type 1) diabetes mellitus. Diabetic Medicine 13, 51.
36. Cuskelly, G.J., McNulty, H. & Scott, J.M. (1996). Effect of increasing dietary folate on red cell folate: implications for prevention of neural tube defects. Lancet 347, 657-659.
37. Daly, L.E., Kirke, P.N., Molloy, A., Weir, D.G. & Scott, J.M. (1995). Folate levels and neural tube defects. Implications for prevention. JAMA: Journal of the American Medical Association 274, 1698-1702.
38. Daly, S., Mills, J.L., Molloy, A.M., Conley, M., Lee, Y.J., Kirke, P.N., Weir, D.G. & Scott, J.M. (1997). Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet 350, 1666-1669.
39. D'Angelo, A. & Selhub, J. (1997). Homocysteine and thrombotic disease. Blood 90, 1-11.
40. De la Haba, G. & Cantoni, G.L. (1959). The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. Journal of Biological Chemistry 234, 603-608.
41. Delport, R., Ubbink, J.B., Vermaak, W.J.H., Rossouw, H., Becker, P.J. & Joubert, J. (1997). Hyperhomocysteinaemia in black patients with cerebral thrombosis. QJM: Monthly Journal of the Association of Physicians 90, 635-639.
42. den Heijer, M.D., Koster, T., Blom, H.J., Bos, G.M.J., Briet, E., Reitsma, P.H., Van den Broucke, J.P. & Rosendaal, F.R. (1996). Hyperhomocysteinemia as a risk factor for deep vein thrombosis. New England Journal of Medicine 334, 759-762.
43. Department of Health (1991) Dietary Reference Values for Food and Energy and Nutrients for the United Kingdom (Report on Health and Social Subjects no. 41). London: HMSO.
44. Dennis, V.W. & Robinson, K. (1996). Homocysteinaemia and vascular disease in end stage renal disease. Kidney International Suppl. 57, S11-17.
45. Drummond, J.T. & Matthews, R.G. (1994). Nitrous oxide inactivation of cobalamin-dependent methionine synthase from Escherichia coli: characterization of the damage to the enzyme and prosthetic group. Biochemistry 33, 3742-3750.
46. Dudman, N.P.B., Wilcken, D.E.L., Wang, J., Lynch, J.F., Macey, D. & Lundberg, P. (1993). Disordered methionine/ homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy and enzymology. Arteriosclerosis and Thrombosis 13, 1253-1260.
47. Edwards, R.L., Levine, J.B., Green, R., Duffy, M., Mathews, E., Brande, W. & Rickles, F.R. (1987). Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Castroenterology 92, 329-337.
48. Engbersen, A.M.T., Franken, D.G., Boers, G.H.J., Stevens, E.M.B., Trijbels, F.J.M. & Blom, H.J. (1995). Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. American Journal of Human Genetics 56, 142-150.
49. Fenton, W.A. & Rosenberg, L.E. (1989). Inherited disorders of cobalamin transport and metabolism. In The Metabolic Basis of Inherited Disease, p. 2065 [C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, editors]. New York: McGraw-Hill.
50. Finkelstein, J.D. (1990). Methionine metabolism in mammals. Journal of Nutritional Biochemistry 1, 228-237.
51. Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R G., Boers, G.J.H., den Heijer, M., Kluijtmans, L.A.J., Van den Heuvel, L.P. & Rozen, R. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 10, 111-113.
52. Fryer, R.H., Wilson, B.D., Gubler, D.B., Fitzgerald, L.A. & Rodgers, G.M. (1993). Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arteriosclerosis and Thrombosis 13, 1327-1333
53. Gallagher, P.M., Meleady, R., Shields, D.S., Tan, K.S., McMaster, D , Rozen, R., Evans, A., Graham, I.M. & Whitehead, A.S. (1996). Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation 94, 2154-2158.
54. Gerritsen, T., Vaughn, J.G. & Waisman, H.A. (1962). The identification of homocystine in the urine. Biochemical and Biophysical Research Communications 9, 493-496.
55. Glueck, C.J., Shaw, P., Lang, J.E., Tracy, T., Sieve-Smith, L. & Wang, Y. (1995). Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. American Journal of Cardiology 75, 132-136.
56. Goyette, P., Frosst, P., Rosenblatt, D.S. & Rozen, R. (1995). Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. American Journal of Human Genetics 56, 1052-1059.
57. Goyette, P., Summer, J.S., Milos, R., Duncan, A.M.V., Rosenblatt, D.S., Matthews, R G. & Rozen, R. (1994). Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nature Genetics 7, 195-200.
58. Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattström, L.E., Ueland, P.M., Palma-Reis, R.J. et al. (1997). Plasma homocysteine as a risk factor for vascular disease. JAMA: Journal of the American Medical Association 277, 1775-1781.
59. Green, R. & Jacobsen, D.W. (1995). Clinical implications of hyperhomocysteinaemia. In Folate in Health and Disease, pp. 75-122 [Lynn Bailey, editor]. New York: Marcel Dekker.
60. Gregory, J.F. (1995). The bioavailability of folate. In Folate in Health and Disease, pp. 195-236 [Lynn B. Bailey, editor]. New York: Marcel Dekker.
61. Gunter, E.W., Bowman, B.A., Caudill, S.P., Twite, D.B., Adams, M.J. & Sampson, E.J. (1996). Results of an international round robin for serum and whole blood folate. Clinical Chemistry 42, 1689-94.
62. Guttormsen, A.B., Ueland, P.M., Nesthus, I., Nygard, O., Schneede, J., Vollset, S.E. & Refsum, H. (1996). Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (<40 μmol/liter) - the Hordaland homocysteine study. Journal of Clinical Investigation 98, 2174-2183.
63. Hajjar, K.A. (1993). Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. Journal of Clinical Investigation 91, 2873-2879.
64. Harker, L.A , Ross, R., Stichter, S.J. & Scott, C.R. (1976). Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. Journal of Clinical Investigation 58, 731-741.
65. Harmon, D.L., Woodside, J.V., Yarnell, J.W.G., McMaster, D., Young, I.S., McCrum, E.E., Gey, K.F., Whitehead, A.S. & Evans, A.E. (1996). The common 'thermo-labile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM: Monthly Journal of the Association of Physicians 89, 571-577.
66. Jackson, L.J., O'Gorman, P.J., O'Connell, J., Cronin, C.C., Cotter, K.P. & Shanahan, F. (1997). Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V. QJM: Monthly Journal of the Association of Physicians 90, 183-188.
67. Jacob, R.A., Wu, M.M., Henning, S.M. & Swendseid, M.E. (1994). Homocysteine increases as folate decreases in plasma of healthy men during short term dietary folate and methyl group restriction. Journal of Nutrition 124, 1072-1080.
68. Jacques. P.F., Bostom, A.G., Williams, R.R., Ellison, R.C., Eckfeldt, J.H., Rosenberg, I.H., Selhub, J. & Rozen, R. (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 93, 7-9.
69. 6 occur commonly in elderly people. American Journal of Clinical Nutrition 58, 468-476
70. Kahn, H.A (1966). The Dorn study of smoking and mortality among US veterans: report on eight and one-half years of observation. National Cancer Institute Monograph 19, 1-125.
71. Kang, S -S., Passen, E.L., Ruggie, N., Kong, P.W.K. & Sora, H. (1993). Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 88, 1463-1469.
72. Kang, S.-S., Wong, P.W.K. & Malinow, M.R. (1992). Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annual Review of Nutrition 12, 279-298.
73. Kang, S.-S., Wong, P.W.K., Susmano, A., Sora, J., Norusis, M. & Ruggie, N. (1991). Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. American Journal of Human Genetics 48, 536-545.
74. Kang, S.-S., Wong, P.W.K., Zhou, J. & Cook, H.Y. (1986). Preliminary report: total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism 35, 889-891.
75. Kang, S.-S., Wong, P.W.K., Zhou, J., Sora, J., Lessick, M., Ruggie, N. & Grcevich, G. (1988a). Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 37, 611-613 (b).
76. Kang, S.-S., Zhou, J., Wong, P.W.K., Kowalisyn, J. & Strokosch, G. (1988b). Intermediate homocysteinaemia: a thermolabile variant of methylenetetrahydrofolate reductase. American Journal of Human Genetics 43, 414-421 (a).
77. Kelly, P., McPartlin, J., Goggins, M., Weir, D.G. & Scott, J.M. (1997). Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. American Journal of Clinical Nutrition 65, 1790-1795.
78. 12 are independent risk factors for neural tube defects. Quarterly Journal of Medicine 86, 703-708.
79. Kluijtmans, L.A.J., van den Heuvel, L.P.W.J., Boers, G.H.J., Frosst, P., Stevens, E.M.B., van Oost, B.A., den Heijer, M., Trijbels, F.J.M., Rosen, R. & Blom, H.J. (1996). Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. American Journal of Human Genetics 58, 35-41.
80. Konecky, N., Malinow, R., Tunick, P.A., Freedberg, R.S., Rosenzweig, B.P., Katz, E.S., Hees, D.L., Upson, B., Leung, B., Perez, J. & Kronzon, I. (1997). Correlation between plasma homocysteine and aortic atherosclerosis. American Heart Journal 133, 534-540.
81. Kraus, J.P. (1994). Molecular basis of phenotype expression in homocysteinuria. Journal of Inherited Metabolic Disease 17, 383-390.
82. Kraus, J.P., Le, K., Swaroop, M., Ohura, T., Tahara, T., Rosenberg, L.E., Roper, M.D. & Kozich, V. (1993). Human cystathionine β-synthase cDNA: sequence, alternative splicing and expression in cultured cells. Human Molecular Genetics 2, 1633-1638.
83. Kutzbach, C. & Stokstad, E.L.R. (1971). Mammalian methylenetetrahydrofolale reductase. Partial purification, properties, and inhibition by S-adenosylmethionine. Biochimica et Biophysica Acta 250, 459-477.
84. Landgren, F., Israelsson, B., Lindgren, A., Hultberg, B , Andersson, A. & Brattström, L. (1995). Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. Journal of Internal Medicine 237, 381-388.
85. Law, M.R., Wald, N.J. & Thompson, S.G. (1994). By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? British Medical Journal 308, 367-372.
86. Lentz, S.R. & Sadler, J.E. (1993). Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 81, 683-689.
87. Levenson, J., Malinow, M.R., Giral, P.H., Razavian, M. & Simon, A. (1994). Increased homocysteine levels in human hypertension. Journal of Hypertension 12(Suppl. 3), S74.
88. Levine, S. (1993). Analytical inaccuracy for folic acid with a popular commercial vitamin B12/ folate kit. Clinical Chemistry 39, 2209-2210.
89. Loscalzo, J. (1996). The oxidant stress of hyperhomocyst(e)inemia. Journal of Clinical Investigation 98, 5-7.
90. Ma, J., Stampfer, M.J., Hennekens, C.H., Frosst, P., Selhub, J., Horsford, J., Malinow, M.R., Willett, W.C. & Rosen, R. (1996). Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 94, 2410-2416.
91. McCully, K.S. (1969). Vascular pathology of homocysteinuria: implications for the pathogenesis of arteriosclerosis. American Journal of Pathology 56, 111-128.
92. McCully, K.S. & Wilson, R.B. (1975). Homocysteine theory of arteriosclerosis. Atherosclerosis 22, 215-227.
93. McGown, E.L., Lewis, C.M., Dong, M.H. & Sauberlich, H.E. (1978). Results with commercial radioassay kits compared with microbiological assay of folate in serum and whole blood. Clinical Chemistry 24, 2186-2191.
94. McKeever, M.P., Weir, D.G., Molloy, A. & Scott, J.M. (1991). Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat, and subcellular distribution in the rat. Clinical Science 81, 551-556.
95. Mahmud, N., Donnelly, S., Molloy, A., McPartlin, J., Casey, E.B., Scott, J. & Weir, D.G. (1998a). Plasma homocysteine is raised in patients with rheumatoid arthritis independent of methylene tetrahydrofolate reductase genotype. British Journal of Rheumatology 37, A154.
96. Mahmud, N., Molloy, A., McPartlin, J., Scott, J.M. & Weir, D.G. (1998b). Homozygosity for methylene reductase C677T variant is associated with low folate and hyperhomocysteinaemia in inflammatory bowel disease patients: important clinical complications. Gastroenterology 114, G4221.
97. Malinow, M.R., Duell, P.B., Hess, D.L. et al. (1998). Reduction in plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. New England Journal of Medicine 338, 1009-1015.
98. Malinow, M.R., Levenson, J., Giral, P., Nieto, F.J., Razavian, M., Segond, P. & Simon, A. (1995). Role of blood pressure, uric acid and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 114, 175-183.
99. Malinow, M.R., Nieto, F.J., Szklo, M., Chambless, L.E. & Bond, G. (1993) Carotid artery intimal medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 87, 1107-1113.
100. Malinow, M.R., Sexton, G., Averbuch, M., Grossman, M., Wilson, D. & Upson, B. (1990). Homocysteinaemia in daily practice: levels in coronary artery disease. Coronary Artery Disease 1, 215-220.
101. Matthews, R.G. (1984). Methionine metabolism in folate and pterins. In Chemistry and Biochemistry of Folates, vol. 1, pp. 497-553 [R.L. Blakley and S.J. Benkovic, editors]. New York: Wiley & Sons.
102. Matthews, R.G. & Haywood, B.J. (1979). Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications. Biochemistry 18, 4845-4851.
103. Mayer, E.L., Jacobsen, D.W. & Robinson, K. (1996) Homocysteine and coronary atherosclerosis. Journal of the American College of Cardiology 27, 517-527.
104. Molloy, A.M., Daly, S., Mills, J.L., Kirke, P.N., Whitehead, A.S., Ramsbottom, D., Conley, M.R., Weir, D.G. & Scott, J.M. (1997). Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 349, 1591-1593.
105. Molloy, A.M., Mills, J.L., Kirke, P.N., Whitehead, A.S., Weir, D.G. & Scott, J.M. (1998). Whole blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radio assay and microbiological assay. Clinical Chemistry (in press).
106. Molloy, A.M. & Scott, J.M. (1998). Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods in Enzymology 281, 43-53.
107. Morrison, H.I., Schaubel, D., Desmeules, M. & Wigle, D.T. (1996). Serum folate and risk of fatal coronary heart disease. JAMA: Journal of the American Medical Association 275, 1893-1896.
108. Mudd, S.H., Finkelstein, J.D., Irreverre, F. & Laster, L. (1964). Homocystinuria: an enzymatic defect. Science 143, 1443-1445.
109. Mudd, S.H., Levy, H.L. & Skovby, F. (1995). Disorders of transsulfuration. In The Metabolic and Molecular Basis of Inherited Disease, pp. 1279-1327 [C.R. Scriver, A.L. Baendet, W. Sly and D. Valle, editors]. New York: McGraw-Hill.
110. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 346, 85-89
111. Neaton, J.D. & Wentworth, D. (1992). Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Archives of Internal Medicine 152, 56-64.
112. Neugebauer, S., Baba, T., Kurokawa, K. & Watanabe, T. (1997). Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 349, 473-474.
113. Nordstrom, M. & Kjellstrom, T. (1992). Age dependency of cystathionine β-synthase activity in human fibroblasts in homocyst(e)inaemia and atherosclerotic vascular disease. Atherosclerosis 94, 213-221.
114. Nygard, O., Nordehaug, J.E., Refsum, H., Ueland, F.M., Farstad, M. & Vollset, S.E. (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. New England Journal of Medicine 337, 230-236.
115. 12. American Journal of Clinical Nutrition 65, 1889-1890.
116. Oakley, G.P. (1997b). Folic acid deficiency's role expands beyond birth defects. Scientist 11, 10-11.
117. Ou, C.-Y., Stevenson, R.F., Brown, V.K., Schwartz, C.E., Allen, W.P., Khoury, M., Oakley, G.P. & Adams, M.J. (1995). C677T homozygosity associated with thermolabile 5,10 methylenetetrahydrofolate reductase as a risk factor for neural tube defects. American Journal of Human Genetics 57, A223.
118. Pancharuniti, N., Lewis, C.A., Sauberlich, H.E., Perkins, L.L., Go, R.C.P., Alvarez, J.O., Macaluso, M., Acton, R.T., Copeland, R.B., Cousins, A.L., Gore, T.B., Cornwell, P.E. & Roseman, J.M. (1994). Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. American Journal of Clinical Nutrition 59, 940-948.
119. Papapetrou, C., Lynch, S.A., Burn, J. & Edwards, Y.H. (1996). Methylenetetrahydrofolate reductase and neural tube defects. Lancet 348, 58.
120. Parfrey, P.S. (1993). Cardiac and cerebrovascular disease in chronic uraemia. American Journal of Kidney Diseases 21, 77-80.
121. Perna, A.F., Ingrosso, D., Galletti, P., Zappia, V. & De Santo, N.G. (1996). Membrane protein damage and methylation reactions in chronic renal failure. Kidney International 50, 358-366.
122. Perry, I.J., Refsum, H., Morris, R.W., Ebrahim, S.B., Ueland, P.M. & Shaper, A.G. (1995). Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346, 1395-1398.
123. Peterson, J.C. & Spena, J.D. (1998). Vitamins and progression of atherosclerosis in hyperhomocysteinaemia. Lancet 351, 263.
124. Petri, M., Roubenoff, R., Dallai, G.E , Nadeau, M.R., Selhub, J. & Rosenberg, I.H. (1996). Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348, 1120-1124.
125. Rasmussen, K., Moller, J., Lyngbak, M., Pedersen, A.M.H. & Dybkjaer, L. (1996). Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clinical Chemistry 42, 630-636.
126. Refsum, H, Ueland, P.M., Nygard, O. & Vollset, S.E. (1998). Homocysteine and cardiovascular disease. Annual Review of Medicine 49, 31-62.
127. Robillon, J.F., Canivet, B., Candito, M., Sadoul, J.L., Jullien, D., Morand, P., Chambon, P. & Freychet, P. (1994). Type I diabetes mellitus and homocyst(e)ine. Diabète et Métabolisme 20, 494-496.
128. Robinson, K., Gupta, A., Dennis, V., Arheart, K., Chaudhary, D., Green, R., Vigo, P., Mayer, E.L., Selhub, J., Kutner, M. & Jacobsen, D.W. (1997). Hyperhomocysteinaemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94, 2743-2748.
129. Robinson, K., Mayer, E., Miller, D., Green, R., van Lente, F , Gupta, A., Kottke-Marchant, K., Savon, S.R., Selhub, J., Nissen, S.E. et al (1995). Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 92, 2825-2830.
130. Rodgers, G.M. & Conn, M.T. (1990). Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 75, 895-901.
131. Rosenblatt, D.S. (1995). Inherited disorders of folate transport. In The Metabolic and Molecular Basis of Inherited Disease, pp. 821-844 [C.R. Scriver, editor]. New York: McGraw-Hill.
132. Roubenoff, R., Delloripa, P., Nadeaa, M R., Abad, L.W., Muldoon, B.A., Selhub, J. & Rosenberg, I.H. (1997). Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis and Rheumatism 40, 718-722.
133. Scott, J.M. & Weir, D.G. (1981). The methyl folate trap. Lancet ii, 337-340.
134. Scott, J.M. & Weir, D.G. (1996). Homocysteine and cardiovascular disease. QJM: Monthly Journal of the Association of Physicians 89, 561-563.
135. Scott, J.M., Dinn, J.J., Wilson, P. & Weir, D.G. (1981). Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet ii, 334-337.
136. Selhub, J., Jacques, P.F., Bostom, A.G., D'Agostino, R.B., Wilson, P.W.F., Belanger, A.J., O'Leary, D.H., Wolf, P.A., Schaefer, E.J. & Rosenberg, I.H. (1995). Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. New England Journal of Medicine 332, 286-291.
137. Selhub, J., Jacques, P.F., Wilson, P.W.F., Rush, D. & Rosenberg, I.H. (1993). Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA: Journal of the American Medical Association 270, 2693-2698.
138. Skovby, F. (1985). Homocystinuria, clinical, biochemical and genetic aspects of cystathionine beta-synthase and its deficiency in man. Acta Paediatrica Scandinavica Suppl. 321, 1-21.
139. Skovby, F., Kraus, J.P. & Rosenberg, L.E. (1984). Biosynthesis of human cystathionine β-synthase in cultured fibroblasts. Journal of Biological Chemistry 259, 583-587.
140. Stabler, S.P., Allen, R.H., Savage, D.G. & Lindenbaum, J. (1990). Clinical spectrum and diagnosis of cobalamin deficiency. Blood 76, 871-881.
141. Stamler, J.S., Osborne, J.A., Jaraki, O., Rabbani, L.E., Mullins, M., Singel, D. & Loscalzo, J. (1993). Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. Journal of Clinical Investigation 91, 308-318.
142. Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., Tishler, P.V. & Hennekens, C.H. (1992). A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA: Journal of the American Medical Association 268, 877-881.
143. Talbot, R.W., Heppell, J., Dozois, R.R. & Beart, R.W. (1986). Vascular complications of inflammatory bowel disease. Mayo Clinic Proceedings 61, 140-145.
144. Tamura, T., Johnston, K.E. & Bergman, S.M. (1996). Homocysteine and folate concentrations in blood from patients treated with hemodialysis. Journal of the American Society of Nephrology 7, 2414-2418.
145. Tsai, J.-C., Perrella, M.A., Yoshizumi, M., Hsieh, C.M., Haber, E., Schlegel, R. & Lee, M.E. (1994). Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proceedings of National Academy of Sciences of the USA 91, 6369-6373.
146. Tsai, M.Y., Bignell, M., Schwichtenberg, K. & Hanson, N.Q. (1996a). High prevalence of a mutation in the cystathionine β-synthase gene. American Journal of Human Genetics 59, 1262-1267.
147. Tsai, M.Y., Garg, U., Key, N.S., Hanson, N.Q., Suh, A. & Schwichtenberg, K. (1996b). Molecular and biochemical approaches in the identification of heterozygotes for homocysteinuria. Atherosclerosis 122, 69-77.
148. Tucker, K.L., Mahnken, B , Wilson, P.W.F., Jacques, P. & Selhub, J. (1996). Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA: Journal of the American Medical Association 276, 1879-1885.
149. Ueland, P.M. & Refsum, H. (1989). Plasma homocysteine - a risk factor for vascular disease: plasma levels in health, disease and drug therapy. Journal of Laboratory and Clinical Medicine 114, 473-501.
150. Ueland, P.M., Refsum, H., Stabler, S.P., Malinow, M.R., Andersson, A. & Allen, R.H. (1993). Total homocysteine in plasma or serum: methods and clinical application. Clinical Chemistry 39, 1764-1779.
151. van Bockxmeer, F.M., Mamotte, C.D.S., Vasikaran, S.D & Taylor, R.R. (1997). Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 95, 21-23.
152. van der Mooren, M.J., Wouters, M.G.A.J., Blom, H J , Schellekens, L.A., Eskes, T.K.A.B. & Rolland, R. (1994). Hormone replacement therapy may reduce high serum homocysteine in post-menopausal women. European Journal of Clinical Investigation 24, 733-736.
153. van der Put, N.M.J., Eskes, T.K.A.B. & Blom, H.J. (1997). Is the common C677C-T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta analysis. QJM: Monthly Journal of the Association of Physicians 90, 111-115.
154. van der Put, N.M.J., Steegers-Theunissen, R.P.M., Frosst, P., Trijbels, F.J.M., Eskes, T.K.A.B., van den Heuvel, L.P., Mariman, E.C M., den Heyer, M., Rozen, R. & Blom, H.J. (1995). Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346, 1070-1071.
155. Vasikaran, B.D. & van Bockxmeer, F.M. (1997). Mild to moderate hyperhomocysteinaemia; a risk factor for vascular disease. Clinical Biochemistry Reviews 18, 55-62.
156. Verhoef, P., Hennekens, C.H., Allen, R.H., Stabler, S.P., Willett, W.C. & Stampfer, M.J. (1997). Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. American Journal of Cardiology 79, 799-801.
157. Verhoef, P., Hennekens, C.H., Malinow, M.R., Koh, F.J., Willett, W.C. & Stampfer, M.J. (1994). A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 25, 1924-1930.
158. Verhoef, P. & Stampfer, M.J. (1995). Prospective studies of homocysteine and cardiovascular disease. Nutrition Reviews 33, 283-288.
159. Wald, N.J., Watt, H.C., Law, M.R., Weir, D.G., McPartlin, J. & Scott, J.M. (1998). Homocysteine and ischaemic heart disease: results of a prospective study with implications on prevention. Archives of Internal Medicine 158, 862-867.
160. Wang, J., Dudman, N.P.B., Wilcken, D.E.L. & Lynch, J.F. (1992). Homocysteine catabolism: levels of 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease. Atherosclerosis 97, 97-106.
161. Ward, M., McNulty, H., McPartlin, J., Strain, J.J., Weir, D.G. & Scott, J.M. (1997). Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM: Monthly Journal of the Association of Physicians 90, 519-524.
162. Weir, D.G. & Scott, J.M. (1995). The biochemical basis of the neuropathy in cobalamin deficiency. In Clinical Haematology: Megaloblastic Anaemia, vol. 8, pp. 479-497 [S.N. Wickramasinghe, editor]. London: Bailliere.
163. Whitehead, A.S., Gallagher, P., Mills, J.L., Kirke, P.N., Burke, H., Molloy, A.M., Weir, D.G., Shields, D.C. & Scott, J.M. (1995). A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. QJM: Monthly Journal of the Association of Physicians 88, 763-766.
164. Wilcken, D.E.L. (1997). MTHFR 677C→T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease. Lancet 350, 603-604.
165. Wilcken, D.E.L., Gupta, V.J. & Reddy, S.G. (1980). Accumulation of sulfur-containing amino acids including cysteine-homocysteine in patients on maintenance hemodialysis. Clinical Science 58, 427-430.
166. Wilcken, D.E.L., Wang, X.L., Sim, A.S. & McCredie, R.M. (1996). Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arteriosclerosis, Thrombosis and Vascular Biology 16, 878-882.
167. Wilcken, D.E.L. & Wilcken, B. (1976). The pathogenesis of coronary artery disease: a possible role for methionine metabolism. Journal of Clinical Investigation 57, 1079-1082.
168. Wild, J., Schorah, C.J., Maude, K. & Levene, M.I. (1996a). Folate intake in young women and their knowledge of preconceptional folate supplementation to prevent neural tube defects European Journal of Obstetrics and Gynecology and Reproductive Biology 70, 185-189.
169. Wild, J., Schorah, C.J., Maude, K. & Levene, M.I. (1996b). Girls should be taught at school about importance of folic acid. British Medical Journal 312, 974.
170. Wouters, M.G.A.J., Moorrees, M.T.E.C., van der Mooren, M.J., Bloom, H.J., Boers, G.H.J., Schellekens, L.A., Thomas, C.M.G. & Eskes, T.K.A.B. (1995). Plasma homocysteine and menopausal status. European Journal of Clinical Investigation 25, 801-805.